Other
Journal
About P&T Journal
Contacts:Editor:
ssherritze@medimedia.com
Advertising:
mliberti@medimedia.com
Circulation:
lgardineer@medimedia.com
Production:
wpeart@medimedia.com
Rate Card
Production Specifications
Statement of Purpose
Guidelines for Authors
Masthead
Editorial Board
Reprints
Recent Issues
April 2007
Features
Editor’s Memo
Goodbye, Larry
P&T pays tribute to a long-time columnist and medical writer, Lawrence Prescott, PhD.
Sonja Sherritze
Commentary
Medication Reconciliation Meets Patient Safety: Irreconcilable Differences?
As with many well-intentioned feel-good initiatives, achieving the goals of the Medication Reconciliation Project will be a lot more difficult than dreaming them up.
Nancy Greengold, MD, MBA
Opinion
Abuse of Stimulant Medications for Attention-Deficit/Hyperactivity Disorder: A New Alternative
Stimulant drugs, considered a first-line therapy for ADHD, have a potential for misuse and abuse. A new agent may have less potential for these problems.
Frank A. López, MD
Cover Story
An Evaluation of Off-Label Use of Recombinant Activated Human Factor VII (NovoSeven): Patient Characteristics, Utilization Trends, and Outcomes from an Electronic Database of U.S. Academic Health Centers
As a therapy for bleeding, rFVIIa is often prescribed for off-label indications, and this trend is increasing. The authors suggest possible new prescribing guidelines.
Sandra Magnetti, MS, DrPH, Michael Oinonen, PharmD, MPH, and Karl A. Matuszewski, MS, PharmD
Meeting Highlights
American Society of Hematology: 48th Annual Meeting and Exposition
The author reviews therapies for multiple myeloma, chronic myeloid leukemia, paroxysmal nocturnal hemolysis, and B-cell chronic lymphocytic leukemia.
Walter Alexander
Pharmaceutical Approval Update
Marvin M. Goldenberg, PhD, RPh, MS
Departments
Editorial
HealthCast 2020
David Nash, MD, MBA, summarizes a series of reports on global trends for a sustainable health care system of the future in terms of health care spending, shared financial risks among private and public payers, and the continuing need for transparency in the quality and pricing of health care.
Marvin M. Goldenberg, PhD, RPh, MS
Medication Errors
Spectrum of Problems with Using Color
Matthew Grissinger, RPh, FASCP, discusses problems with color coding in pharmaceutical products.
Matthew Grissinger, RPh, FASCP
Prescription: Washington
Generic Biotechnology Drugs Could Win Congressional Approval; FDA Approval Would Be Trickier
Stephen Barlas predicts that it will be a lot easier for Congress to authorize the FDA to oversee the approval of generic biotech drugs than it will be for the FDA to implement the approval process.
Stephen Barlas
New Drugs/Drug News/New Medical Devices
P&T presents the latest information from the FDA.
Drug Forecast
Rimonabant (Acomplia): The First Cannabinoid-1 Receptor Blocker for Obesity
The authors review rimonabant (Acomplia) for the treatment of obesity.
Carla A. Luque, PharmD, Megan J. Ehret, PharmD, and Jose A. Rey, PharmD, BCPP
